ReviewTheScientificWorldJournal2014
Next generation sequencing: potential and application in drug discovery.
Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 21 citations in OpenAlex.
- Identification of potential pathways and microRNA-mRNA networks associated with benzene metabolite hydroquinone-induced hematotoxicity in human leukemia K562 cells.BMC pharmacology & toxicology · 2022Article
- A protein interactions map of multiple organ systems associated with COVID-19 disease.Genomics & informatics · 2021Article
- Retracted: Next Generation Sequencing: Potential and Application in Drug Discovery.TheScientificWorldJournal · 2020Article
- Studying human disease using human neurons.Brain research · 2017Review
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?PPAR research · 2015Review
- High-Performance Integrated Virtual Environment (HIVE) Tools and Applications for Big Data Analysis.Genes · 2014Article
Corrections and comments
- Correction · 2014-11-19Concerns/Issues about Authorship/Affiliation · Error in Text · Updated to Retraction ·
- Retraction · 2020-08-25Euphemisms for Plagiarism · Plagiarism of Text · Upgrade/Update of Prior Notice(s) ·
- Erratum issuedSrivastava, A K [added]; Bansode, F W [added]
- Retracted
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world has now entered into a new era of genomics because of the continued advancements in the next generation high throughput sequencing technologies, which includes sequencing by synthesis-fluorescent in situ sequencing (FISSEQ), pyrosequencing, sequencing by ligation using polony amplification, supported oligonucleotide detection (SOLiD), sequencing by hybridization along with sequencing by ligation, and nanopore technology. Great impacts of these methods can be seen for solving the genome related problems of plant and animal kingdom that will open the door of a new era of genomics. This may ultimately overcome the Sanger sequencing that ruled for 30 years. NGS is expected to advance and make the drug discovery process more rapid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.